NCT06204341 - Towards Optimal Treatment for High Risk Prostate Cancer | Biotech Hunter

Enrollment

207

Participants

Timeline

Start Date

January 2, 2024

Primary Completion Date

December 18, 2032

Study Completion Date

December 18, 2032

Conditions

High Risk Prostate Carcinoma

Interventions

RADIATION

HYPOPRIME treatment

Hypo fractionated pelvic radiotherapy with boost to primary tumour in the prostate with elective lymph node irradiation and minimized androgen deprivation therapy

Trial Locations (1)

2262 BA

RECRUITING

Haaglanden Medical Centre, Leidschendam